Dissemination of current treatment research findings to the profession, policy makers and patients - Whose responsibility is it?

Addiction

Volumn 95, Issue 12, 2000, Pages 1767-1768

  Crome, I B ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BUPRENORPHINE; DIAMORPHINE; LEVACETYLMETHADOL;

ADVERTIZING; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG MARKETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE POLICY; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; NOTE; TREATMENT OUTCOME;

HUMANS; INFORMATION SERVICES; PUBLIC RELATIONS; RESEARCH; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 0034531107     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (20)

1. Ultra rapid detoxification: A look at what is happening in Spain
2. A pilot study of naltrexone accelerated detoxification in opioid dependence
3. Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for inpatient opiate detoxification
4. Deaths in the first two weeks of maintenance treatment in NSW in 1994: Identifying cases of iatrogenic methadone toxicity
5. Addiction treatment and the making of large claims
6. The development of a unique designated community service for adolescents: Policy, prevention and education implications
7. First, do no harm: Naltrex-one accelerated detoxification
8. Factors affecting motivation to treatment in severely dependent alcoholics
9. Innovation in the pharmaceutical industry
10. Overdose, suicide attempts and death among a cohort of naltrexone treated opioid addicts
11. Inpatient substance abuse care and the outcome of subsequent residential and out patient care
12. Suicide among drug addicts in the UK
13. Ondansetron to treat early onset alcoholism?
14. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addiction previously treated without success
15. Long term outcomes of alcohol use disorders: Comparing untreated individuals with those in Alcoholics Anonymous and formal treatment
16. Active surveillance of adverse effects associated with naltrexone in New South Wales
17. Clinical experience with antagonist-induced opiate withdrawal under anaesthesia
18. Deaths in methadone maintenance treatment in New South Wales, Australia, 1990-1995